{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T23:25:11Z","timestamp":1781047511513,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research and Cultivation Fund of Capital Medical University","award":["PYZ21157"],"award-info":[{"award-number":["PYZ21157"]}]},{"name":"Institutional Grant of Beijing Shijitan Hospital, Capital Medical University","award":["2017-c04"],"award-info":[{"award-number":["2017-c04"]}]},{"name":"Capital\u2019s Funds for Health Improvement and Research","award":["2018-1-2151"],"award-info":[{"award-number":["2018-1-2151"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to compare the efficacy and safety of high-dose methotrexate (HD-MTX) versus teniposide (TEN) in patients with newly diagnosed immunocompetent primary central nervous system lymphomas (PCNSLs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study included immunocompetent, adult patients with newly diagnosed PCNSL at 22 centers in China from 2007 to 2016. The patients received HD-MTX or TEN as first-line induction therapy. The objective response rate, progression-free survival, and overall survival were analyzed for each patient cohort.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 96 patients were eligible: 62 received HD-MTX, while 34 received teniposide. The overall response rate was 73.2% and 72.7% in the MTX and the TEN cohorts, respectively (<jats:italic>P<\/jats:italic>\u2009=\u20090.627). The median progression-free survival was 28.4\u00a0months [95% confidence interval (CI): 13.7\u201351.2] in the MTX cohort and 24.3\u00a0months (95% CI: 16.6\u201332.1) in the TEN cohort (<jats:italic>P<\/jats:italic>\u2009=\u20090.75). The median overall survival was 31\u00a0months (95% CI: 26.8\u201335.2) in the MTX cohort and 32\u00a0months (95% CI: 27.6\u201336.4) in the TEN cohort (<jats:italic>P<\/jats:italic>\u2009=\u20090.77). The incidence of any grade of coagulopathy\/deep-vein thrombosis and gastrointestinal disorders was significantly higher in the MTX cohort than in the TEN cohort; no significant difference was found in the incidence of other adverse events between the two cohorts.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This was the first multicenter study using TEN as the main agent compared with HD-MTX in newly diagnosed primary CNS lymphoma. The TEN-based regimen was non-inferior to the HD-MTX-based regimen with similar overall responses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Classification of evidence<\/jats:title>\n                <jats:p>This study provided Class III evidence that the teniposide-based regimen was non-inferior to high-dose methotrexate\u2009\u2212\u2009based regimen with similar overall responses and long-time survival in immunocompetent patients with PCNSL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-023-11268-5","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T09:02:43Z","timestamp":1691744563000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study"],"prefix":"10.1186","volume":"23","author":[{"given":"Kaili","family":"Zhong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaohua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningju","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aichun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizheng","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"11268_CR1","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1038\/bjc.2011.357","volume":"105","author":"JL Villano","year":"2011","unstructured":"Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414\u20138.","journal-title":"Br J Cancer"},{"key":"11268_CR2","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","volume":"374","author":"AJ Ferreri","year":"2009","unstructured":"Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009;374:1512\u201320.","journal-title":"Lancet"},{"key":"11268_CR3","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s00277-016-2602-5","volume":"95","author":"V Zeremski","year":"2016","unstructured":"Zeremski V, Koehler M, Fischer T, Schalk E. Characteristics and outcome of patients with primary CNS lymphoma in a \u201creal-life\u201d setting compared to a clinical trial. Ann Hematol. 2016;95:793\u20139.","journal-title":"Ann Hematol"},{"key":"11268_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/asheducation-2016.1.379","volume":"2016","author":"TT Batchelor","year":"2016","unstructured":"Batchelor TT. Primary central nervous system lymphoma. Hematology Am Soc Hematol Educ Program. 2016;2016:379\u201385.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"11268_CR5","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","volume":"31","author":"JL Rubenstein","year":"2013","unstructured":"Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;31:3061\u20138.","journal-title":"J Clin Oncol"},{"key":"11268_CR6","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","volume":"31","author":"PG Morris","year":"2013","unstructured":"Morris PG, Correa DD, Yahalom J, Raizer JJ, Schiff D, Grant B, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971\u20139.","journal-title":"J Clin Oncol"},{"key":"11268_CR7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s11060-017-2435-7","volume":"133","author":"C Houillier","year":"2017","unstructured":"Houillier C, Ghesquieres H, Chabrot C, Soussain C, Ahle G, Choquet S, et al. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study. J Neurooncol. 2017;133:315\u201320.","journal-title":"J Neurooncol"},{"key":"11268_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/hon.2037","volume":"31","author":"S Mappa","year":"2013","unstructured":"Mappa S, Marturano E, Licata G, Frezzato M, Frungillo N, Ilariucci F, et al. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Hematol Oncol. 2013;31:143\u201350.","journal-title":"Hematol Oncol"},{"key":"11268_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","volume":"11","author":"E Thiel","year":"2010","unstructured":"Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036\u201347.","journal-title":"Lancet Oncol"},{"key":"11268_CR10","doi-asserted-by":"publisher","first-page":"4730","DOI":"10.1200\/JCO.2007.12.5062","volume":"25","author":"GD Shah","year":"2007","unstructured":"Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007;25:4730\u20135.","journal-title":"J Clin Oncol"},{"key":"11268_CR11","doi-asserted-by":"publisher","first-page":"4570","DOI":"10.1200\/JCO.2006.06.6910","volume":"24","author":"IT Gavrilovic","year":"2006","unstructured":"Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006;24:4570\u20134.","journal-title":"J Clin Oncol"},{"key":"11268_CR12","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/neuonc\/noq011","volume":"12","author":"MC Chamberlain","year":"2010","unstructured":"Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010;12:736\u201344.","journal-title":"Neuro Oncol"},{"key":"11268_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/1097-0142(20000915)89:6<1359::AID-CNCR21>3.0.CO;2-9","volume":"89","author":"GM Mead","year":"2000","unstructured":"Mead GM, Bleehen NM, Gregor A, Bullimore J, Shirley D, Rampling RP, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer. 2000;89:1359\u201370.","journal-title":"Cancer"},{"key":"11268_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1158\/0008-5472.CAN-07-1874","volume":"68","author":"R Aneja","year":"2008","unstructured":"Aneja R, Liu M, Yates C, Gao J, Dong X, Zhou B, et al. Multidrug resistance-associated protein-overexpressing teniposide-resistant human lymphomas undergo apoptosis by a tubulin-binding agent. Cancer Res. 2008;68:1495\u2013503.","journal-title":"Cancer Res"},{"key":"11268_CR15","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.7314\/APJCP.2014.15.11.4733","volume":"15","author":"JJ Wu","year":"2014","unstructured":"Wu JJ, Wang XH, Li L, Li X, Zhang L, Sun ZC, et al. Fotemustine, teniposide and dexamethasone in treating patients with CNS lymphoma. Asian Pac J Cancer Prev. 2014;15:4733\u20138.","journal-title":"Asian Pac J Cancer Prev"},{"key":"11268_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jsps.2016.04.001","volume":"24","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Liu G, Lang M, Zhang J, Geng J. Patients treatment with neuroglioma by teniposide and semustine and its influence on Twist and E-cadherin expression. Saudi Pharm J. 2016;24:299\u2013304.","journal-title":"Saudi Pharm J"},{"key":"11268_CR17","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s002800050665","volume":"40","author":"O van Tellingen","year":"1997","unstructured":"van Tellingen O, Boogerd W, Nooijen WJ, Beijnen JH. The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue. Cancer Chemother Pharmacol. 1997;40:330\u20134.","journal-title":"Cancer Chemother Pharmacol"},{"key":"11268_CR18","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","volume":"21","author":"PM Poortmans","year":"2003","unstructured":"Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van\u2019t Veer M, Hansen M, Soubeyran P, et al. High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol. 2003;21:4483\u20138.","journal-title":"J Clin Oncol"},{"key":"11268_CR19","first-page":"2097","volume":"19","author":"YX Wang","year":"2020","unstructured":"Wang YX, Huang Y, Xu XP, Chen BB, Lin ZG, Ma Y, et al. Curative effect of methotrexate combined with teniposide in the treatment of primary central nervous system lymphoma. Oncol Lett. 2020;19:2097\u2013106.","journal-title":"Oncol Lett"},{"key":"11268_CR20","first-page":"445","volume":"27","author":"KL Zhong","year":"2015","unstructured":"Zhong KL, Xia XB, Da Y, Chen XL, Liu J, Zhang WJ, et al. Teniposide-based regimen for 16 patients with primary central nervous system lymphoma. Cancer Res Clinic. 2015;27:445\u2013338.","journal-title":"Cancer Res Clinic"},{"key":"11268_CR21","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","volume":"23","author":"LE Abrey","year":"2005","unstructured":"Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034\u201343.","journal-title":"J Clin Oncol"},{"key":"11268_CR22","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","volume":"21","author":"AJ Ferreri","year":"2003","unstructured":"Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266\u201372.","journal-title":"J Clin Oncol"},{"key":"11268_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1212\/WNL.0000000000000593","volume":"83","author":"M Holdhoff","year":"2014","unstructured":"Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, et al. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014;83:235\u20139.","journal-title":"Neurology"},{"key":"11268_CR24","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/leu.2016.334","volume":"31","author":"K Fritsch","year":"2017","unstructured":"Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Mohle R, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31:846\u201352.","journal-title":"Leukemia"},{"key":"11268_CR25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11060-018-2970-x","volume":"140","author":"J Wu","year":"2018","unstructured":"Wu J, Duan L, Zhang L, Sun Z, Fu X, Li X, et al. Fotemustine, teniposide and dexamethasone versus high-dose methotrexate plus cytarabine in newly diagnosed primary CNS lymphoma: a randomised phase 2 trial. J Neurooncol. 2018;140:427\u201334.","journal-title":"J Neurooncol"},{"key":"11268_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1080\/10428194.2018.1474524","volume":"60","author":"H Chan","year":"2019","unstructured":"Chan H, Moraes FY, Berlin A, Crump M, Mason W, Laperriere N, et al. Significance of treatment response when managing patients with primary central nervous system lymphoma. Leuk Lymphoma. 2019;60:349\u201357.","journal-title":"Leuk Lymphoma"},{"key":"11268_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood-2016-01-650101","volume":"128","author":"B Kasenda","year":"2016","unstructured":"Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT. The role of whole brain radiation in primary CNS lymphoma. Blood. 2016;128:32\u20136.","journal-title":"Blood"},{"key":"11268_CR28","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","volume":"3","author":"AJ Ferreri","year":"2016","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217\u201327.","journal-title":"Lancet Haematol"},{"key":"11268_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/hon.2666","volume":"37","author":"AM Schmitt","year":"2019","unstructured":"Schmitt AM, Herbrand AK, Fox CP, Bakunina K, Bromberg JEC, Cwynarski K, et al. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis. Hematol Oncol. 2019;37:548\u201357.","journal-title":"Hematol Oncol"},{"key":"11268_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s11912-020-00941-8","volume":"22","author":"JEC Bromberg","year":"2020","unstructured":"Bromberg JEC, van der Meulen M, Doorduijn JK. The Role of Rituximab in Primary Central Nervous System Lymphoma. Curr Oncol Rep. 2020;22:78.","journal-title":"Curr Oncol Rep"},{"key":"11268_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/neuonc\/nox187","volume":"20","author":"JS Mendez","year":"2018","unstructured":"Mendez JS, Ostrom QT, Gittleman H, Kruchko C, DeAngelis LM, Barnholtz-Sloan JS, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. Neuro Oncol. 2018;20:687\u201394.","journal-title":"Neuro Oncol"},{"key":"11268_CR32","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.16592","volume":"190","author":"N Martinez-Calle","year":"2020","unstructured":"Martinez-Calle N, Poynton E, Alchawaf A, Kassam S, Horan M, Rafferty M, et al. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival. Br J Haematol. 2020;190:394\u2013404.","journal-title":"Br J Haematol"},{"key":"11268_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000499100","volume":"142","author":"A Tempaku","year":"2019","unstructured":"Tempaku A, Takahashi Y, Kamada H. Therapeutic outcomes and toxicity of high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma: a report on six cases. Acta Haematol. 2019;142:190\u20132.","journal-title":"Acta Haematol"},{"key":"11268_CR34","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","volume":"24","author":"LE Abrey","year":"2006","unstructured":"Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711\u20135.","journal-title":"J Clin Oncol"},{"key":"11268_CR35","doi-asserted-by":"publisher","first-page":"e00928","DOI":"10.1002\/brb3.928","volume":"8","author":"G Jahr","year":"2018","unstructured":"Jahr G, Broi MD, Holte H Jr, Beiske K, Meling TR. Evaluation of Memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict Overall Survival in intracranial Primary CNS lymphoma. Brain Behav. 2018;8:e00928.","journal-title":"Brain Behav"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11268-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11268-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:18:11Z","timestamp":1700486291000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11268-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11268"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11268-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"assertion":[{"value":"15 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The scientific research project was approved by the Scientific Research Ethics Committee of Beijing Shijitan Hospital, Capital Medical University (# Research Ethics Review of 2019 No. (56)). Informed consent was waived by the Scientific Research Ethics Committee of Beijing Shijitan Hospital, Capital Medical University due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"746"}}